Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for vaso-occlusive crisis in children with sickle cell disease
2019-000839-21Phase 2Withdrawn
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of aprepitant in sickle cell disease (SCD) (2 arms), sponsored by Centre Hospitalier Intercommunal de Créteil. Primary endpoint: Cumulative morphine dose during hospitalization. Planned start Apr 2019; status: withdrawn.
02
Drugs
aprepitant
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2019-000839-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000839-21.